Comparative Pharmacology
Head-to-head clinical analysis: KEVEYIS versus NEPTAZANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEVEYIS versus NEPTAZANE.
KEVEYIS vs NEPTAZANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Keveyis (dichlorphenamide) is a carbonic anhydrase inhibitor. It reduces the frequency of attacks in primary hyperkalemic periodic paralysis by decreasing intracellular pH, which stabilizes muscle cell membranes and reduces potassium efflux from muscle cells.
Methazolamide is a carbonic anhydrase inhibitor. It decreases intraocular pressure by inhibiting carbonic anhydrase in the ciliary epithelium, reducing aqueous humor secretion. It also has weak diuretic effects due to renal carbonic anhydrase inhibition.
50 mg orally twice daily with food; may increase to 100 mg twice daily after 2 weeks if needed.
50 mg orally twice daily, increasing to 50 mg three times daily if needed. Maximum dose: 200 mg daily.
None Documented
None Documented
Terminal elimination half-life: 15–20 hours following a single oral dose; at steady state, half-life 42–80 hours (mean ~60 h) due to dose-dependent kinetics.
Terminal elimination half-life: 8-12 hours. In renal impairment, half-life may extend to 20-30 hours, requiring dose adjustment.
Primarily renal: unchanged drug accounts for ~82% of dose in urine; fecal excretion <5%; minor hepatic metabolism.
Renal: 100% as unchanged drug via tubular secretion. No biliary or fecal elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor